NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 41 min 5 sec ago

Alcohol Impairment of Immune Function, Host Defense and Tissue Homeostasis (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 11:02
Funding Opportunity PA-18-191 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from researchers with broad expertise to study the consequences of alcohol consumption on immune function with a goal toward improving the outcome of patients who abuse alcohol.
Categories: NIH-Funding

Clarifying the Relationship between Delirium and Alzheimers Disease and Related Dementias (R21/R33 Clinical Trial Optional)

Wed, 11/01/2017 - 10:59
Funding Opportunity PAR-18-181 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.
Categories: NIH-Funding

Natural History of Disorders Identifiable by Screening of Newborns (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:57
Funding Opportunity PAR-18-090 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field.In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.
Categories: NIH-Funding

HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:48
Funding Opportunity PAS-18-063 from the NIH Guide for Grants and Contracts. The National Institutes of Health has recently announced the HIV/AIDS research priorities for the next three to five years http://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html. The goal of this Funding Opportunity Announcement (FOA) is to stimulate high priority research relevant to drug abuse and HIV/AIDS.
Categories: NIH-Funding

Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:46
Funding Opportunity PAR-18-062 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.
Categories: NIH-Funding

The Application of Big Data Analytics to Drug Abuse Research (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:43
Funding Opportunity PA-18-057 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage the application of Big Data analytics to reveal deeper or novel insights into the biological and behavioral processes associated with substance abuse and addiction.NIDA recognizes that to accelerate progress toward understanding how the human brain and behavior is altered by chronic drug use and addiction, it is vital to develop more powerful analytical methods and visualization tools that can help capture the richness of data being generated from genetic, epigenetic, molecular, proteomic, metabolomic, brain-imaging, micro-electrode, behavioral, clinical, social, services, environmental studies as well as data generated from electronic health records.Applications for this FOA should develop and/or utilize computational approaches for analyzing large, complex datasets acquired from drug addiction research.The rapid increase of technologies to acquire unprecedented amounts of neurobiological and behavioral data, and an expanding capacity to store those data, results in great opportunity to bring to bear the power of the computational methods of Big Data analytics on drug abuse and addiction.
Categories: NIH-Funding

Ancillary Studies to Major Ongoing Clinical Research Studies to Advance Areas of Scientific Interest within the Mission of the NIDDK (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:40
Funding Opportunity PAR-18-042 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to accelerate the pace and expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within its mission by leveraging ongoing large, multi-center clinical research studies through ancillary studies.This Funding Opportunity Announcement (FOA) invites research project applications to conduct ancillary studies to major ongoing clinical research studies, including clinical trials and prospective observational studies. Applications submitted to this FOA must propose to collect new information and/or biological samples directly from participants of the ongoing parent study, and must address new research questions that are beyond those specified in the approved protocol of the parent study and are within the scientific mission of the NIDDK. This FOA cannot be used to extend the duration of the parent study.
Categories: NIH-Funding

Outcome Measures for Use in Treatment Trials of Individuals with Intellectual and Developmental Disabilities (R01- Clinical Trial Optional)

Wed, 11/01/2017 - 10:35
Funding Opportunity PAR-18-039 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications from institutions/organizations that propose to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities (IDD). This FOA will address a significant need in the field, one that is especially apparent in efforts to develop pharmacological treatments for these populations. This FOA will focus ongoing clinical and translational research on a neglected area essential for therapy and pharmacological treatment development. Potential applicants may also be interested in the FOA Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01).
Categories: NIH-Funding

Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:33
Funding Opportunity PA-18-032 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions/organizations which propose to characterize or identify factors in early childhood (birth-24 months) that may increase or mitigate risk for obesity and/or excessive weight gain and/or to fill methodological research gaps relevant to the understanding of risk for development of obesity in children. Studies should propose research in children from birth to 24 months, although any proposed follow-up assessments, if applicable, may continue past this period. Studies may also assess factors relevant to families and/or caregivers of children from birth to 24 months. Applications should seek to fill unique research needs and involve expertise across disciplines as appropriate for the proposed research question.
Categories: NIH-Funding

Nutrigenetics and Nutrigenomics Approaches for Nutrition Research (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:32
Funding Opportunity PA-18-034 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to promote application of nutrigenetics and/or nutrigenomics approaches to nutrition research through collaborative interaction among nutrition researchers and experts in omics technologies.
Categories: NIH-Funding

Improving Quality of Care and Quality of Life for Persons with Alzheimers Disease and Related Dementias at the End of Life (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:28
Funding Opportunity PAS-18-030 from the NIH Guide for Grants and Contracts. This FOA invites applications that address clinical and translational research gaps in the study of end-of-life care needs in order to improve quality of life at the end of life of people with Alzheimers disease and related dementias (ADRD) and their families. Research that either employs (a) secondary analysis of existing data from longitudinal cohort studies or from administrative records or (b) primary data collection for Stage I behavioral intervention development is particularly encouraged.
Categories: NIH-Funding

Phenotypic and Functional Studies on FOXO3 Human Longevity Variants to Inform Potential Therapeutic Target Identification Research (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:22
Funding Opportunity PAR-18-026 from the NIH Guide for Grants and Contracts. The focus of this Funding Opportunity Announcement (FOA) is on in vivo human studies, and in vitro studies on human cells or tissues, aimed at potential identification of therapeutic targets or and/or testing of interventions for healthy aging. Potential therapeutic targets include FOXO3 itself and upstream and downstream regulators in pathways mediated by FOXO3. The range of research areas of interest in this FOA includes studies that: 1) examine in vivo phenotypic effects of human FOXO3 variants, and/or 2) elucidate effects of these variants on cellular functions and the pathways that mediate them, and/or 3) identify and evaluate candidate therapeutic targets (e.g., target validation studies, testing of candidate compounds) for potential interventions based on FOXO3 functional pathways.
Categories: NIH-Funding

Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:05
Funding Opportunity PA-18-025 from the NIH Guide for Grants and Contracts. Data from clinical studies of metformin in a variety of patient populations suggest that it may have other effects, besides being an antihyperglycemic agent, which warrant further attention in translational aging research. The objective of this FOA is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformins human physiologic and cellular effects that would be useful in identifying novel molecular targets.
Categories: NIH-Funding

Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:03
Funding Opportunity PAR-18-009 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status. A distinguishing feature of each application will be formation of an academic-industrial partnership, which is a strategic alliance of investigators in academic, industrial, and any other entities who work together as partners to identify and translate a technological solution or mitigation of a cancer-related problem.
Categories: NIH-Funding

Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)

Wed, 11/01/2017 - 10:00
Funding Opportunity PA-18-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. This FOA will not support phase III clinical trials.
Categories: NIH-Funding

NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35)- Clinical Trial Not Allowed

Wed, 11/01/2017 - 07:37
Funding Opportunity RFA-DE-18-011 from the NIH Guide for Grants and Contracts. The objective of the NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.
Categories: NIH-Funding

Mobile and Connected Health Interventions to Improve Care Continuum and Health Outcomes among Youth with HIV (R34)

Wed, 11/01/2017 - 03:30
Funding Opportunity RFA-MH-18-605 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to develop and test the next generation of interventions delivered through mobile health (mHealth) technology to improve diagnosis, linkage to care, retention in care, and viral suppression among youth living with human immunodeficiency virus (YLWH). This FOA supports planning for a clinical trial and can include a small pilot clinical trial that a) incorporates emerging and cutting edge technologies to enhance outcomes along the HIV care continuum, b) supports real-time clinical decision making, and c) facilitates effective long-term management of HIV. Critical to this FOA, proposed research should identify specific patient outcomes along the HIV care continuum that are expected to improve from technological approaches.
Categories: NIH-Funding

Mobile and Connected Health Interventions to Improve Care Continuum and Health Outcomes among Youth with HIV (R01)

Wed, 11/01/2017 - 03:30
Funding Opportunity RFA-MH-18-606 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to develop and test the next generation of interventions delivered through mobile health (mHealth) technology to improve diagnosis, linkage to care, retention in care, and viral suppression among youth living with human immunodeficiency virus (YLWH). This FOA supports clinical trials that a) incorporate emerging and cutting edge technologies to enhance outcomes along the HIV care continuum, b) support real-time clinical decision making, and c) facilitate effective long-term management of HIV. Critical to this FOA, proposed research should identify specific patient outcomes along the HIV care continuum that are expected to improve from technological approaches.
Categories: NIH-Funding

George M. O'Brien Urology Cooperative Research Centers Program (U54-Clinical Trial Optional)

Wed, 11/01/2017 - 02:28
Funding Opportunity RFA-DK-17-013 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for the George M. OBrien Urology Cooperative Research Centers Program. This program will provide a coordinated platform for multidisciplinary interactions between basic and clinical scientists with the overall goal of understanding the etiology and development of benign urologic diseases and disorders, and providing a collaborative venue to design better treatments, diagnostics, and prevention strategies for these disease conditions within the NIDDK mission interests. This program will also serve as a national resource to the larger urological research community and provide educational enrichment opportunities to scientists electing to pursue research in benign urology. Accordingly, applications are sought from individuals willing to cooperate with the NIDDK under a cooperative centers program. The funded Centers will work with the NIDDK in facilitating research collaborations and interactions within and among centers and with the larger research community to accomplish the overall goal of improving treatment of urologic disorders through enhanced communication and research excellence.
Categories: NIH-Funding